Trial Information

Summary: Cushing's Disease Study CSOM230B2305

Novartis Oncology is conducting this clinical research study is to determine the most safe and effective dose of an investigational drug for participants 18 years of age and older who have ACTH-dependent Cushing's disease. An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Participants will be required to inject themselves twice a day with the study medication and will be asked to visit the study center 17 times over 1 year.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: September 5, 2008 at 3:14:38 PM